title: Use of indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection.
authors.affiliation: St. Francis Regional Medical Center, Raritan, NJ.
authors.forename: C F
authors.initials: CF
authors.lastname: Shield
authors.forename: L
authors.initials: L
authors.lastname: Kahana
authors.forename: J
authors.initials: J
authors.lastname: Pirsch
authors.forename: P
authors.initials: P
authors.lastname: Vergne-Marini
authors.forename: M R
authors.initials: MR
authors.lastname: First
authors.forename: T J
authors.initials: TJ
authors.lastname: Schroeder
authors.forename: D
authors.initials: D
authors.lastname: Cohen
authors.forename: D J
authors.initials: DJ
authors.lastname: Norman
authors.forename: A
authors.initials: A
authors.lastname: Monaco
authors.forename: A
authors.initials: A
authors.lastname: Martinez
mesh_terms: D000328:Adult; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D006084:Graft Rejection; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000009:adverse effects*; D014184:Transplantation, Homologous
chemical_list: D016207:Cytokines; D016853:Muromonab-CD3; D007213:Indomethacin